Work

Homocysteine Reduction and Vascular–Metabolic Changes During PCSK9 Inhibition in Familial Hypercholesterolemia:A Prospective Cohort Study

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, but their effects on homocysteine (Hcy) and broader vascular–metabolic pathways remain poorly characterized. Objective To evaluate changes in plasma Hcy and related vascular–metabolic biomarkers during PCSK9 inhibitor treatment in patients with familial hypercholesterolemia (FH). Methods In this prospective, single-center observational cohort study, 50 patients with FH initiating a PCSK9 inhibitor were evaluated at baseline and after 12 weeks. The primary endpoint was the within-subject change in plasma Hcy. Paired assessments included lipid parameters, urinary oxidative stress markers, biomarkers of the arginine–nitric oxide pathway, and ancillary untargeted metabolomic profiling. Results Mean Hcy decreased from 12.6 ± 6.7 to 8.9 ± 2.4 µmol/L, a 29% reduction, while median Hcy decreased from 10.7 µmol/L (IQR, 9.0–13.4) to 9.1 µmol/L (IQR, 7.0–10.5), a 15% reduction (P < 0.001). Hyperhomocysteinemia (> 15 µmol/L) resolved in all 10 affected patients (P = 0.002). Total cholesterol, corrected LDL-C, and lipoprotein(a) decreased by 37.9%, 34.1%, and 35.2%, respectively. Urinary F₂-isoprostanes, DH-isoprostanes, and dinor-isoprostane metabolites also decreased significantly, whereas arginine–nitric oxide pathway biomarkers did not. Multivariable analysis identified coordinated associations between ΔHcy and methylmalonic acid, arginine–nitric oxide metabolites, LDL-C reduction, and lipoprotein(a). Metabolomics showed sterol and phospholipid remodeling, lower choline abundance, and a higher putative betaine-related signal. Conclusion PCSK9 inhibition was associated with reduced Hcy, marked lipid remodeling, and lower oxidative stress in FH, supporting further investigation of Hcy as a treatment-responsive biomarker of broader vascular–metabolic remodeling. This response may help characterize vascular biology during intensive lipid-lowering therapy in high-risk FH.
Authors: Ilenia Lorenza Calcaterra(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing), Guido D'Errico(Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Carmine De Luca(Data curation, Investigation, Writing – review & editing), Antonella Tufano(Investigation, Methodology, Supervision, Writing – review & editing), Gabriella Iannuzzo(Investigation, Methodology, Writing – review & editing), Alessandro Di Minno(Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing), Paola Ciciola(Data curation, Investigation, Writing – review & editing), Chiara Caputo(Data curation, Investigation, Writing – review & editing), Maria Donata Di Taranto(Investigation, Methodology, Writing – review & editing), Giuliana Fortunato(Methodology, Supervision, Writing – review & editing), Mauro Amato(Investigation, Methodology, Writing – review & editing), Gualtiero Colombo(Investigation, Methodology, Writing – review & editing), Roberta Baetta(Investigation, Methodology, Writing – review & editing), Daniela Coggi(Investigation, Methodology, Writing – review & editing), Damiano Baldassarre(Conceptualization, Methodology, Supervision, Writing – review & editing), Matteo Di Minno(Conceptualization, Methodology, Project administration, Supervision, Writing – review & editing)
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236328539
Cites: 30
Cited by:
Related to: 10